KPV: The Three-Amino-Acid Anti-Inflammatory

KPV is three amino acids long. That's not a typo. Lys-Pro-Val — the tail end of alpha-MSH — is among the shortest peptides anyone in this space runs, and it does something genuinely useful: it puts the brakes on NF-kB, the master inflammatory switch inside your cells.

For people with IBD, chronic gut inflammation, or an autoimmune flare that won't quiet down, KPV has developed a reputation as the quiet workhorse — less famous than BPC-157, often stacked with it, and in a few specific use cases arguably more targeted.

What it is, in one paragraph

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH). Research in the 1990s and 2000s showed that most of alpha-MSH's anti-inflammatory activity lives in this tiny tail — without the pigmentation-inducing effects of the full molecule. KPV inhibits NF-kB signaling inside cells, dampening production of TNF-alpha, IL-6, IL-8, and the other cytokines that drive inflammatory cascades. It also has modest antimicrobial activity against certain bacteria and candida strains. Almost all the solid evidence is preclinical — mouse colitis models, cell culture — but the signal is consistent enough that it's made its way deep into community gut protocols.

Dosing: what people actually do

KPV is one of the few peptides where the oral route has real community support:

Sub-Q (systemic):

• Starting: 200 mcg once daily
• Target: 500 mcg once daily
• Cycle: 4–6 weeks on, 2–4 weeks off

Oral (gut-targeted):

• 200–500 mcg once daily on empty stomach
• Same cycle length

The oral route works because KPV is absorbed through the PepT1 transporter in intestinal epithelium — the same route your body uses for small dietary peptides. It's one of the rare peptides that genuinely does something when swallowed, rather than being destroyed in the stomach like BPC-157 or TB-500 would be.

"Did a 5-week run at 500 mcg oral, empty stomach, first thing in the morning. I'm not going to call it a cure but the daily inflammation baseline dropped noticeably by week 3. Bloating, joint stuff, skin. Came back after I stopped but slower than before." — forum user

What it pairs with

• BPC-157. The canonical gut stack. BPC-157 drives tissue repair and angiogenesis; KPV shuts down the inflammatory signaling that's keeping the damage open. They work on different mechanisms and the reports of them together are consistent enough that this is the default IBD-adjacent protocol.
• Thymosin alpha-1 if there's an immune-modulation angle on top of the inflammation.
• LL-37 occasionally shows up in antimicrobial-plus-anti-inflammatory skin protocols with KPV, though that's a more specialized use case.

What it doesn't pair with: anything that's already strongly anti-inflammatory and hitting NF-kB from another angle (high-dose prescription anti-inflammatories). You're not going to hurt yourself, you're just stacking redundant mechanisms.

Red flags

KPV has one of the cleaner side effect profiles in the peptide space, which is partly why it's used so widely:

• Injection-site reactions — rare. Mostly with the sub-Q route.
• Mild GI flipping when starting oral — typically resolves in a few days.
• Nothing else systemic is reliably reported in community protocols or the research.

The cleanest read on KPV is: it's a small peptide that dampens a specific inflammatory pathway. It's not a systemic immunosuppressant. It's not pushing hormones around. It's not obvious how it would cause the kinds of problems other peptides in the space can.

Honest limits

• All the convincing data is preclinical. No completed human clinical trials specific to KPV have been published. That's less damning than it sounds — the preclinical data is mechanistically clean, and the safety profile in actual use is good — but it is a gap.
• Half-life is short. Plasma half-life is measured in minutes. The intracellular accumulation via PepT1 is what probably extends the actual duration of effect at inflamed tissue.
• Targeted delivery is still an active research area. Nanoparticle formulations developed for KPV aren't really in the community supply chain yet; what most people run is just the bare tripeptide.
• It's anti-inflammatory, not reparative. KPV calms the signaling that keeps damage open; it doesn't rebuild tissue. That's why it pairs naturally with BPC-157, which does the opposite job.

Where to go next

• NF-kB mechanism detail, the alpha-MSH origin story, and the colitis literature: Pepperpedia KPV entry.
• Reconstitution math and oral vs. sub-Q dose planning: peppercalc.com.
• Real gut-protocol reports and BPC/KPV stack logs: Protocol Discussions forum.